Nafarelin

The bulky lipophilic D-2-naphthylalanine at position 6 gives nafarelin roughly 200-fold the potency of native GnRH and enough lipophilicity to cross nasal mucosa, which is what makes intranasal delivery viable for a decapeptide. Nasal bioavailability is nonetheless only around 2 to 3 percent, so the delivered dose is small and adherence matters a great deal - a missed spray or a blocked nose meaningfully reduces suppression. As with all agonists, the first two weeks produce a flare before oestradiol or testosterone falls to postmenopausal or prepubertal levels.

Targets: GnRH receptor (GnRHR), Pituitary gonadotrophs, LH, FSH, Oestradiol

• · 400 mcg daily as one 200 mcg spray per nostril, morning and evening. If amenorrhoea does not occur, the label permits increasing to 800 mcg daily as one spray into each nostril morning and evening. Started between cycle days 2 and 4; treatment is limited to 6 months because of bone loss, and repeat courses are not recommended.
• · Continued until the appropriate age for puberty to resume. Poor adherence with an eight-spray daily regimen is the usual reason for treatment failure.

Work out your exact syringe units →

• very commonHot flushes— Reported by around 90 percent of women in endometriosis trials.
• commonNasal irritation— Unique to this route.
• commonVaginal dryness
• commonHeadache
• commonEmotional lability and depressed mood
• commonAcne, oily skin and mild hirsutism— Androgenic effects reported with nafarelin specifically.
• commonBone mineral density loss— Roughly 5 to 6 percent vertebral loss over 6 months, largely but not fully recovered afterwards.
• uncommonOvarian cyst formation— Typically in the first two months from the flare.

• Pregnancy and breastfeeding.
• Undiagnosed abnormal vaginal bleeding.
• Known hypersensitivity to GnRH analogues.
• Pre-existing osteoporosis or major risk factors for it.

• conflictNasal decongestants — Using one within 2 hours of a dose reduces absorption of an already low-bioavailability drug; the Synarel label requires at least a 2-hour gap.
• conflictgonadorelin — Desensitises the receptor gonadorelin needs.
• synergyAdd-back hormone therapy — Reduces bone loss and vasomotor symptoms during longer courses.

• · Confirm amenorrhoea within 8 weeks in endometriosis; continued bleeding suggests inadequate dosing or absorption.
• · In precocious puberty, LH response to GnRH stimulation, growth velocity and bone age.
• · Bone density if therapy extends beyond 6 months.

Prescription drug in the US and EU.

• Synarel (nafarelin acetate) nasal solution prescribing information (label)
• Henzl et al. 1988, administration of nasal nafarelin as compared with oral danazol for endometriosis, New England Journal of Medicine (trial)

Pharmacodynamically nafarelin is an ordinary continuous GnRH agonist - flare, then receptor uncoupling and downregulation, then hypogonadal hormone levels. What is genuinely distinctive is that the whole therapeutic effect has to be pushed through a nasal mucosa that absorbs less than three percent of what you spray, and that constraint shapes everything about how the drug behaves in practice. Because delivery is so inefficient and so variable, adherence is not a soft virtue here but a pharmacological requirement: a missed evening spray in a twice-daily endometriosis regimen removes half a day's already-marginal exposure, and in central precocious puberty the regimen is eight sprays a day, which is a genuinely difficult thing to ask of a child and a family. Poor adherence, not resistance, is the usual reason precocious puberty fails to suppress on nafarelin. The 2.8 percent figure also explains the decongestant warning being unusually firm for a label - washing the dose out of the nose before it is absorbed removes a large fraction of a small number. The other feature worth noting is the long-lived metabolite, with an 85.5 hour half-life against the parent's 3 hours. It is not thought to be pharmacologically important, but it means the exposure profile is more prolonged than a three-hour half-life suggests, and it is one reason twice-daily nasal dosing achieves sustained receptor occupancy at all.

Treatment failure is usually delivery failure. Somebody with a persistent blocked nose, allergic rhinitis or a decongestant habit absorbs a fraction of an already small dose, keeps bleeding, and is told the drug did not work. Check technique, check the decongestant gap, and use the label-sanctioned step-up before concluding anything. In central precocious puberty the eight-spray daily regimen is a genuine adherence problem, and it is the usual reason a child fails to suppress - which matters because inadequate suppression means continuing bone age advancement and lost adult height. Bone loss is the other real harm: 8.7 percent vertebral trabecular loss over six months, only partly recovered, is why courses are capped and repeat courses are not recommended. Ovarian cysts in the first two months come from the flare and usually resolve. The androgenic complaints - acne, oily skin, mild hirsutism - are more prominent with nafarelin than with the rest of the class and catch people by surprise.

1. 400 mcgEndometriosis, from cycle day 2 to 4 — One 200 mcg spray into one nostril each morning and one into the other nostril each evening. This is the standard starting and usual maintenance dose.
2. 800 mcgEndometriosis, if amenorrhoea has not occurred after about 2 months — One spray into each nostril morning and evening. The label explicitly permits this step-up, and it is a real titration rather than a theoretical one, because absorption varies so much between people.
3. 1.6 mgCentral precocious puberty, starting dose — Two sprays into each nostril morning and evening - eight sprays a day. Adherence to this is the single biggest determinant of success.
4. 1.8 mgCentral precocious puberty, if suppression is inadequate — The label permits stepping up to 1800 mcg daily. Check technique and adherence before concluding the dose is too low.

• GnRH receptor (GnRHR) on pituitary gonadotrophs — Approximately 200-fold the potency of native GnRH; a specific Kd was not resolved here.

  Flare followed by downregulation with continuous twice-daily or four-times-daily nasal dosing, producing postmenopausal oestradiol in women and prepubertal hormone levels in children.

• Ovarian oestradiol production (indirect)

  Suppression to postmenopausal levels, which is what produces amenorrhoea and endometriotic lesion regression - and also the hot flushes, vaginal dryness and bone loss.

• Androgen receptor-mediated effects (unexplained)

  Acne, oily skin and mild hirsutism are reported specifically with nafarelin more than with other agents in the class. The mechanism is not settled but it is a consistent enough signal to warn people about.

• Synarel endometriosis registration programme 3 · 24 weeks

  Reduction in endometriosis symptoms and laparoscopically assessed lesion burden over six months, with nafarelin compared against danazol. Established efficacy and the six-month course limit driven by bone loss.

• Nafarelin in central precocious puberty 3

  Suppression of GnRH-stimulated peak LH to prepubertal levels, with growth velocity and bone age advancement as supporting endpoints.

Serum concentrations peak 10 to 40 minutes after a spray. The flare occupies the first one to two weeks. Amenorrhoea in endometriosis typically arrives at 4 to 8 weeks, and its absence past that point is the trigger to act rather than wait. Hot flushes begin as oestradiol falls. Symptomatic improvement in endometriosis pain generally follows amenorrhoea by a few weeks. Bone loss is measurable at six months. In precocious puberty, suppression of the axis develops over one to three months and treatment continues for years, stopping around the age at which puberty should proceed. Menses typically return 4 to 8 weeks after the last dose.

The one interaction that genuinely matters is topical nasal decongestants, and it is not a subtle effect - washing a dose out of a nose that only absorbs 2.8 percent of it in the first place is a large proportional loss, which is why the label demands at least a two-hour gap. The same logic applies to nasal steroids, saline rinses and blowing your nose immediately after spraying. Add-back hormone therapy - low-dose oestrogen with a progestogen, or norethisterone - is the established way to reduce bone loss and vasomotor symptoms during longer courses and does not abolish the therapeutic effect. Gonadorelin is inert against a downregulated receptor. Nothing in this class combines usefully with another GnRH analogue.

Against every other GnRH analogue here, nafarelin's distinguishing feature is the route rather than the pharmacology, and the route is a mixed blessing. No needles and no implant procedure is genuinely valuable, particularly in children, but 2.8 percent bioavailability with a fourfold interindividual spread and a twice or four-times daily schedule is a lot of variability to accept in exchange. Against leuprolide depot or a goserelin implant for the same indications, nafarelin demands far more of the patient and delivers less reliable suppression. Its niche status is about adherence, not efficacy. Against danazol, the older comparator in endometriosis, nafarelin has fewer androgenic effects overall but is not free of them, and it trades danazol's metabolic and lipid problems for bone loss.

$700–$1200/month. Synarel has been priced in the several-hundred to over a thousand dollar range per 8 mL bottle in the US, and an endometriosis regimen uses roughly one bottle a month while precocious puberty regimens use considerably more. Generic nasal nafarelin availability has been limited. Figures are indicative and were not verified in this session.

• ?The three-letter sequence is reconstructed from the D-2-naphthylalanine substitution described in the Core record rather than re-verified against a primary structural source in this session.
• ?Volume of distribution and clearance are not stated in the label and were not sourced elsewhere.
• ?The 80 percent protein binding figure is the label's value measured at 4 degrees C, which is not a physiological condition and should be treated as approximate.
• ?The two trials listed are marked unverified. The endometriosis and precocious puberty registration programmes plainly exist and underpin the approval, but I did not resolve the specific publications, participant numbers or years in this session.
• ?The Henzl 1988 New England Journal of Medicine nafarelin versus danazol trial referenced in the Core record was not located in PubMed during this session and is therefore not cited here.
• ?Cost figures are indicative and were not verified in this session.

• SYNAREL (nafarelin acetate) nasal solution - FDA prescribing information DailyMed / FDA

  Source of the 2.8 percent bioavailability with its 1.2 to 5.6 percent range, the 10 to 40 minute tmax, 80 percent protein binding, the 85.5 hour metabolite half-life, the excretion split, the decongestant warning and the specific bone density numbers.

• The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis Whitehouse RW, Adams JE, Bancroft K, Vaughan-Williams CA, Elstein M, Clinical Endocrinology, 1990 · PMID 2147597

  Direct measurement of the bone cost of a six-month nafarelin course against danazol, which is the trade-off the six-month label cap exists to manage.